MetaCap

Edesa Biotech (EDSA) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 17.6% versus a loss of 77.2%. Over five years, EDSA leads with a -95.6% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $27.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDSA+17.65%RNTX-77.24%
+1028%+449%-130%
Nov 21, 20251 yearNov 20, 2026
EDSA-95.72%RNTX-97.57%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDSA versus RNTX key metrics
MetricEDSARNTX
Share price$2.00$0.3369
Market cap$27.02M$29.06M
1-day change-8.05%-8.38%
YTD return+40.85%-70.96%
1-year return+17.65%-77.24%
5-year return-95.63%-97.47%
EPS (TTM)$-1.72$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-7.19M$-49.87M
52-week high$20.32$2.10
52-week low$0.72$0.284
Distance from 52-week high-90.16%-83.96%
Analyst consensusnonenone
Avg. price target upside+716.50%+1680.94%
Average volume1.45M586.68K
Shares outstanding13.51M86.27M
Employees1710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed RNTX by 94.9 percentage points over the past year.

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

EDSA vs RNTX FAQ

Which is bigger, Edesa Biotech or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $27.02M for Edesa Biotech (EDSA).

Which stock has performed better over the past year, EDSA or RNTX?

EDSA returned +17.65% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Edesa Biotech and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons